Deals Shaping The Medical Industry, October 2014
Executive Summary
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced August-September 2014.
You may also be interested in...
RenalGuard Gets Capital Infusion To Push AKI-Prevention Device Into US
RenalGuard Solutions has attracted $14.5m from investors and will use the funds to take its novel device, designed to prevent acute kidney injury following cardiac interventional procedures, into the US.
US FDA’s Proposed Sunscreen Order Due In Days With Inquiry Ongoing Re Environmental Impacts
Industry anticipates a proposed administrative order from the US FDA by 27 September on OTC sunscreen drug products, including GRASE status of active ingredients. Meanwhile, the agency’s probe continues into UV filter environmental impacts, and the National Academy of Sciences is gathering information to weigh those possible ills against human health consequences of reduced sunscreen use.
Paying For Gene Therapy: Biggest Cost Challenges Two To Three Years Away?
Only about one-quarter of the 40 gene therapies projected to launch by the end of 2025 would have potential US patient populations of more than 50,000. But a handful of treatments could target millions of individuals.